The Readout LOUD

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come. Subscribe today on iTunes, SoundCloud, and Stitcher.

Play
The Readout LOUD

Listen: Another Alzheimer’s setback, crypto for biotech, and a blessing of unicorns

By Damian Garde and Rebecca Robbins

Play
The Readout LOUD

Listen: CRISPR upheaval, Celgene’s chutzpah, and canine genomics

By Damian Garde and Rebecca Robbins

The Readout LOUD

LISTEN: FDA furloughs, ’80s pop radio, and video game therapeutics

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: A people’s history of J.P. Morgan

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Watson’s latest stumble, a glimpse into the crystal ball, and revisiting Sarepta

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Gilead’s new boss, the year that was, and the thing about DNA tests

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Using the word ‘cure,’ an FDA loophole, & making biotech history

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Your guide to the #CRISPRbabies controversy

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: What the midterms mean, a golden age on hold, and the $4 million drug

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Biotech’s October surprise, the precise cost of precision, and breaking postpartum silence

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Pharma at the ballot box, the latest Alzheimer’s argument, and truly personalized medicine

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Drug prices on TV, immortal blockbusters, and genetic privacy

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Fake friends at the FDA, cancer counter-narratives, and biotech’s bear turn

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Nobel snubs, millennial founders, and a new kind of lightning round

By Rebecca Robbins and Megan Thielking

The Readout LOUD

LISTEN: A fish oil epiphany, VC monopolies, and ketamine clinics

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: A Hong Kong heat-check, a $20 million wrist slap, and pharma’s (other) diversity problem

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Founders’ funds, doctors’ disclosures, and the subtle art of beeping

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: A genome-editing flop, a Celgene Senate hopeful, and a live audience

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: FDA shows its teeth, biotech fish oil might be pointless, & the quest to cure McCain’s cancer

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: A genome-editing first, Trump on Wall Street, and biotech red flags

By Damian Garde and Rebecca Robbins

The Readout LOUD

LISTEN: A lesson in startup jargon, pharma’s bare Alzheimer’s cupboard, and the cost of CAR-T

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: Insider trading goes to Washington, online bloodshed over fake meat, & doctors vs. fund managers

By Damian Garde and Rebecca Robbins

The Readout LOUD

LISTEN: Biotech’s sellers market, Sanofi’s second act, and literally climbing Mt. Everest

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

LISTEN: A debatable Alzheimer’s breakthrough, Gilead’s golden age, and separating smart money from dumb

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: Pharma at the midterms, CRISPR’s latest crack-up, and your guide to earnings

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: Trump’s telephonic prowess, Biogen’s mysterious future, & the rise of ‘hypelines’

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

The Readout LOUD

LISTEN: Biotech’s six months of surprise, the shaky road ahead, and sell-side self-doubt

By Damian Garde and Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy